News10/12/2025
Formation Bio licenses LNK01006 into Bleecker Bio
Formation Bio, Inc. →Formation Bio acquired worldwide rights excluding Greater China to Lynk Pharmaceuticals’ LNK01006, a CNS-penetrant TYK2 inhibitor, for development in Bleecker Bio. Lynk receives a minority equity interest in that subsidiary, an upfront payment, contingent development, regulatory and commercial milestones, and tiered royalties. The upfront and potential milestones total up to [figure hidden]; the ceiling is not completed consideration. Pacific Bridge NY is a minority co-investor in Bleecker Bio, not established here as an investor in Formation Bio’s parent. The announcement reported FDA IND clearance and planned first-half-2026 Phase 1 entry.